Registration Progress |堃博医疗 Achieves Dual Breakthroughs in the Asian Market, Multiple Products Approved in Hong Kong and Indonesia

Recently, the self-developedBroncAblate® Zhiheng® Pulmonary Radiofrequency Ablation System(including radiofrequency treatment equipment and single-use pulmonary radiofrequency ablation catheters, hereinafter referred to as 'Zhiheng®') has officially been listed in the Hong Kong Department of Health’s medical device registry (registration approval). This marks the formal commercial rollout in Hong Kong of the world's first natural-orifice radiofrequency ablation interventional device for lung cancer. Concurrently,FleXNeedleCN Single-Use Endoscopic Suction Biopsy Needlealso received registration approval from the Hong Kong Department of Health’s medical device registry.

This follows the approval in Hong Kong of products such as Lung Point Plus, Archimedes, and Tuokuo® BroncTru®, with more innovative products from Kunbo Medical entering the precision pulmonary interventional diagnosis and treatment market in Hong Kong. These enrich the regional product portfolio and provide new precision interventional treatment options for local patients with lung diseases.

Recently,Tuokuo® BroncTru® Single-Use Bronchoscopic Dilation Catheter(hereinafter referred to as 'Tuokuo®') successfully obtained approval from the Indonesian Ministry of Health, marking a new breakthrough in the Southeast Asian market.

Under the guidance of a navigation system, Tuokuo® can precisely reach extraluminal lesion sites, especially peripheral solitary pulmonary nodules invisible under X-ray, establishing a direct channel to the lesion for diagnosis and subsequent treatment across the entire lung.